Journal article
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)
Abstract
BACKGROUND: The COMPASS trial (Cardiovascular Outcomes for People using Anticoagulation Strategies) demonstrated that dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily versus aspirin 100 mg once daily reduced the primary major adverse cardiovascular event (MACE) outcome of cardiovascular death, myocardial infarction, or stroke, as well as, mortality, in patients with chronic coronary syndromes or …
Authors
Bainey KR; Welsh RC; Connolly SJ; Marsden T; Bosch J; Fox KAA; Steg PG; Vinereanu D; Connolly DL; Berkowitz SD
Journal
Circulation, Vol. 141, No. 14, pp. 1141–1151
Publisher
Wolters Kluwer
Publication Date
April 7, 2020
DOI
10.1161/circulationaha.119.044598
ISSN
0009-7322